Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Small Cap Foreign Biotech -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (37)	2/28/2000 7:02:00 PM
From: nigel bates	Read Replies (3) \| Respond to of 363

Not sure if this is the right place to post, but I'm looking at a biotech fund with a large % of unquoted biotechs. The largest unquoted holdings (valued at cost) are the following - Advanced Corneal Systems Inc, Align Technology Inc, AtheroGenics Inc, ( www.athergenics.com sch-plough.com ) Biovector Therapeutics SA, ( biovector.com ) Capteur Sensors Ltd, Chimeric Therapies Inc, ( chimeric.com ) Cobra Therapeutics Ltd, EOS Biotechnology Inc, ( eosbiotech.com ) Florigene Ltd, Metris Therapeutics Ltd, MitoKor Inc, ( mitokor.com ) Molecular Staging Inc, ( molecularstaging.com ) Peptor ltd, Pointshare Corp, ( hkn.com ) Small Molecule Therapeutics Inc, UroTherapies Inc ( urotherapies.com ) anyone recognise any ? The fund (Biotech Investments Ltd.) trades at a c 15% discount to asset value. It's registered in Bermuda or somewhere at the moment, but is moving domicile to the UK. They had about 10% of OGS before it floated, so I'm wondering if there are any other hidden gems in there. I've put the quoted US investments on SI - siliconinvestor.com nig

To: RWReeves who wrote (37)	8/21/2000 12:25:19 AM
From: Henrik	Respond to of 363

Novogen anti-cancer drug trials advance NOVOGEN LIMITED 2000-08-21 ASX-SIGNAL-G HOMEX - Sydney Australian pharmaceutical company, Novogen, today announced that its anti-cancer drug, NV06, has advanced to its next stage of clinical trialing. The Company has received approval for NV06 to enter a Phase 1-11 trial and that trial now is to commence at a major Australian teaching hospital. The trial will involve 36 patients with solid metastatic cancers. The cancers will be predominantly prostate and breast cancers that have failed previously to respond fully to standard anti-cancer drugs. This trial involves a treatment strategy of single weekly injections, a strategy that allows large doses of drug to be given. Patients will receive single weekly injections for 12 weeks. Novogen announced in June 2000 that it had successfully completed a Phase 1a study that involved administering a single intravenous injection of NV06 to cancer patients. That study established that the drug was well tolerated by the patients and was chemically stable in the bloodstream. The objectives of this new trial are to assess the effects of longer-term therapy on safety and cancer progression. NOVOGEN ANNOUNCES COMPLETION OF NV06 INFUSION STUDY Novogen also announces the completion of a Phase 1a study of NV06 delivered by infusion. Constant infusion is an alternative treatment strategy to single weekly injections and aims to deliver a steady, low level of drug on a long-term basis. Certain types of cancer respond well to this form of treatment. This Phase la study was successful in confirming that a steady-state blood level of NV06 could be maintained by chronic infusion and that the procedure was well tolerated. Results of the current studies will form part of a submission to the United States, Food and Drug Administration (FDA) for approval for human clinical trials to be conducted in cancer patients in the USA. NV06 is a new class of anti-cancer drug that has been designed to target cancer cells while sparing normal cells. In the laboratory, NV06 displays potent anti-cancer activity against a wide range of human cancers, but shows little or no activity against non-cancer cells. Pre-clinical studies have provided the drug with a high safety profile. Novogen has completed a pilot production facility for the manufacture of NV06 to approved pharmaceutical standards and will continue to manufacture the drug throughout the clinical development program. NV06 is being developed with the assistance of the Australian Government's START research and development program, Issued for NOVOGEN LIMITED Listings ASX (CODE NRT) NASDAQ(CODE NVGN) For further Information Christopher Naughton, MANAGING DIRECTOR Professor Alan Husband, RESEARCH DIRECTOR, Novogen Limited TEL (02) 9878 0088 novogen.com Issued by Westbrook Communications CONTACT: David Reid TEL (02) 9231 0922 OR 0417 217 157